Search
Research
Neonatal sepsis: a systematic review of core outcomes from randomised clinical trialsThe lack of a consensus definition of neonatal sepsis and a core outcome set proves a substantial impediment to research that influences policy and practice relevant to key stakeholders, patients and parents.
Research
Rhinoviruses A and C elicit long-lasting antibody responses with limited cross-neutralizationRhinoviruses (RVs) can cause severe wheezing illnesses in young children and patients with asthma. Vaccine development has been hampered by the multitude of RV types with little information about cross-neutralization. We previously showed that neutralizing antibody (nAb) responses to RV-C are detected twofold to threefold more often than those to RV-A throughout childhood. Based on those findings, we hypothesized that RV-C infections are more likely to induce either cross-neutralizing or longer-lasting antibody responses compared with RV-A infections.
Research
Anaphylactic Reactions During Bee Venom Immunotherapy in the Paediatric PopulationA retrospective study will review episodes of anaphylaxis during bee venom immunotherapy in children, any modifications made to the dosing schedule, and the subsequent outcomes over a nine-year period in Western Australia.
Research
Per Os to Protection – Targeting the Oral Route to Enhance Immune-mediated Protection from Disease of the Human NewbornValerie Verhasselt MD, PhD Head, Immunology and Breastfeeding 0402997617 Valerie.verhasselt@thekids.org.au Head, Immunology and Breastfeeding @
Research
Effect of maternal prebiotic supplementation on human milk immunological composition: Insights from the SYMBA studyImmunomodulatory proteins in human milk (HM) can shape infant immune development. However, strategies to modulate their levels are currently unknown. This study investigated whether maternal prebiotic supplementation alters the levels of immunomodulatory proteins in HM.
News & Events
Researcher joins national push to unlock the secrets behind MSA The Kids Research Institute Australia researcher will work to better understand the immune system mechanisms that cause multiple sclerosis, thanks to a new grant from MS Australia.
Research
Short-course, high-dose primaquine regimens for the treatment of liver-stage vivax malaria in childrenTo assess the pharmacokinetics, safety, and tolerability of two high-dose, short-course primaquine (PQ) regimens compared with standard care in children with Plasmodium vivax infections.
Research
IFNβ Is a Potent Adjuvant for Cancer Vaccination StrategiesCancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model.
Research
Two cases of Leclercia adecarboxylata septic arthritis in immunocompetent paediatric patientsLeclercia adecarboxylata is a rare cause of septic arthritis in children, and has intrinsic resistance to common antibiotics. We describe two cases of L. adecarboxylata septic arthritis in children that required re-presentation to hospital with prolonged treatment, and highlight the importance of considering L. adecarboxylata as a potential cause of infection among children with penetrating injuries and associated environmental exposure.
Research
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine(PNEU-PLAN)Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV.